APA (7th ed.) Citation

Reshef, R., Luger, S., Loren, A., Frey, N., Goldstein, S., Hexner, E., . . . Porter, D. (2011). Feasibility, Safety and Efficacy of Maraviroc, a CCR5 Antagonist, in Graft-Versus-Host Disease Prevention After Reduced intensity Conditioned (RIC) Allogeneic Stem Cell Transplant (SCT): A Phase I/II Study. Biology of Blood & Marrow Transplantation, 17(2), S331. https://doi.org/10.1016/j.bbmt.2010.12.532

Chicago Style (17th ed.) Citation

Reshef, R., et al. "Feasibility, Safety and Efficacy of Maraviroc, a CCR5 Antagonist, in Graft-Versus-Host Disease Prevention After Reduced Intensity Conditioned (RIC) Allogeneic Stem Cell Transplant (SCT): A Phase I/II Study." Biology of Blood & Marrow Transplantation 17, no. 2 (2011): S331. https://doi.org/10.1016/j.bbmt.2010.12.532.

MLA (9th ed.) Citation

Reshef, R., et al. "Feasibility, Safety and Efficacy of Maraviroc, a CCR5 Antagonist, in Graft-Versus-Host Disease Prevention After Reduced Intensity Conditioned (RIC) Allogeneic Stem Cell Transplant (SCT): A Phase I/II Study." Biology of Blood & Marrow Transplantation, vol. 17, no. 2, 2011, p. S331, https://doi.org/10.1016/j.bbmt.2010.12.532.